Please login to the form below
Clementia Pharmaceuticals
This page shows the latest Clementia Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.
Ipsen buys rare disease group Clementia in $1.3bn deal
Will acquire lead multiple rare disease candidate palovarotene. Ipsen is set to pay out a total of $1.3bn to buy Clementia Pharmaceuticals in a move that will significantly boost its ... The acquisition of Clementia Pharmaceuticals accelerates the
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Featured jobs
- Brand Manager - Medium Global Pharma Company
-
£Competitive Financial Package
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
-
Account director
-
Competitive salary and bonus scheme
-
Account Manager
-
£Competitive Salary
- Senior Medical Writer or Lead Medical Writer
-
£Competitive Salary
-
Account Manager (PR)
-
Great Benefits
-
Senior External Communications Lead
-
£Competitive Salary
-
Publications director
-
Competitive salary and bonus scheme
- Digital Associate Director - Medcomms
-
£65000 - £80000 per annum
- Group Director of Medical Affairs and Scientific Strategy, Medic...
-
Substantial six figure package
- Senior Medical Writer, MedComms Agency
-
Salary TBC
-
Experienced medical editor
-
Competitive salary and bonus scheme
-
Account Director
-
£Competitive Salary
-
Account Director, Medical Education
-
Salary TBC
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
- Account Director, Healthcare Communications
-
Salary TBC
Subscribe to our email news alerts
- Immutep spikes on trial of its LAG-3 drug with Keytruda
- US backs Sanofi’s ‘fast-track’ coronavirus vaccine
- Coronavirus outbreak escalation could impact drug supply chain
- Researchers discover new antibiotic using AI
- Genital herpes vaccine candidate heads for human studies
- Roche’s Herceptin/Perjeta fixed-dose combo filed with FDA
- AVENIR GLOBAL appoints global healthcare lead
- Bedrock Group bolsters team with three key appointments
- AXON recognised for ‘excellence in wellbeing’ by Great Place to Work
- Celgene’s Revlimid scores NICE approval in follicular lymphoma
- Lilly’s Cyramza narrowly clears FDA adcomm vote for first-line NSCLC
- Menlo slumps as itching drug fails mid-stage trial
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- The ALS patient journey
- Nick Goldup is the Director of Care Improvement at the Motor Neuron Disease Association (MNDA). Here, he offers his insights into the journey for patients with ALS and explores the...
- Equipping your medical affairs teams with solutions to navigate the healthcare landscape
- Dr Tyler Ray, OPEN Health Medical Communications...
- Can protein degraders unlock ‘undruggable’ drug targets?
- Exploring a new and exciting area of small-molecule drug discovery...
Quick links
Infographics
